▶ 의학신문:

혁신 알파 방사선 암 치료법 ‘알파타우메디컬’ 나스닥 입성

http://www.bosa.co.kr/news/articleView.html?idxno=2169492 

▶ PR newswire :

Alpha Tau Is Expected to Commence Trading on Nasdaq Under the Ticker "DRTS" on March 8, 2022

https://www.prnewswire.com/news-releases/alpha-tau-medical-and-healthcare-capital-corp-announce-completion-of-business-combination-301496675.html 

▶ globenewswire : 

Healthcare Capital Corp. and Alpha Tau Medical Ltd. Announce Stockholder Approval of the Business Combination 

https://www.globenewswire.com/news-release/2022/02/22/2389181/0/en/Healthcare-Capital-Corp-and-Alpha-Tau-Medical-Ltd-Announce-Stockholder-Approval-of-the-Business-Combination.html 

▶ 메디파나 :

美나스닥 스팩 상장 앞둔 '알파타우', 목표주가 18달러

http://medipana.com/news/news_viewer.asp?NewsNum=291943&MainKind=A&NewsKind=5&vCount=12&vKind=1

▶ 알파타우 홈페이지(영문) :

https://www.alphatau.com/single-post/results-of-first-us-clinical-trial-of-alpha-dart

▶ 메디컬투데이 :

알파타우, 악성 피부 ‧연조직 암 ‘알파다트’ 첫 美 임상 결과 발표…“심각한 부작용 없어”

https://mdtoday.co.kr/news/view/1065579392131834 

▶ 팜뉴스 :

알파타우 '알파다트',12주 치료 10개 종양 모두 완전관해...심각한 부작용 없어

https://www.pharmnews.com/news/articleView.html?idxno=200247